Drug Trial Radar · NCT05736731
A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression
Last checked: Nov 20, 2026Latest source record: Apr 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
160
Planned (sponsor's estimate)
Start
Apr 28, 2023
Primary completion
Dec 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- A2 Biotherapeutics Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Tempus AI
- First posted
- Feb 21, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this study is to test A2B530,an autologous logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), and other solid tumors that express CEA and have lost HLA-A\*02 expression. The main questions this study aims to answer are: * Phase 1: What is the maximum or recommended dose of A2B530 that is safe for patients * Phase 2: Does the recommended dose of A2B530 kill the solid tumor cells and protect the patient's healthy cells Participants will be required to perform study procedures and assessments, and will also receive the following study treatments: * Enrollment and Apheresis in BASECAMP-1 (NCT04981119) * Preconditioning Lymphodepletion (PCLD) Regimen * A2B530 Tmod CAR T cells at the assigned dose
Conditions
- Solid Tumor, Adult
- Solid Tumor
- Pancreatic Cancer
- Pancreatic Neoplasms
- Pancreas Cancer
- Non Small Cell Lung Cancer
- Non Small Cell Lung Cancer Recurrent
- Non-Small Cell Squamous Lung Cancer
- NSCLC
- NSCLC, Recurrent
- Colorectal Cancer
- Colorectal Neoplasms
- Colorectal Adenocarcinoma
- CRC
- Colorectal Cancer Metastatic
- Cancer
Interventions
A2B530Biological
Autologous logic-gated Tmod CAR T-cells
xT-Onco with HLA-LOH AssayDiagnostic test
An investigational next generation sequencing (NGS) in vitro diagnostic (IVD) medical device
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1: Rate of adverse events and dose limiting toxicities (DLTs) by dose levelTime frame: From the time of Informed consent until 24 months (2 years) post A2B530 infusion.
- Phase 1: Recommended Phase 2 Dose (RP2D)Time frame: 21 days post A2B530 infusion
- Phase 2: The Overall Response Rate (ORR) for patientsTime frame: 24 months post A2B530 infusion
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Banner Health
Gilbert, Arizona
University of California San Diego
La Jolla, California
UCLA Medical Center
Los Angeles, California
Moffitt Cancer Center
Tampa, Florida
Mayo Clinic Rochester
Rochester, Minnesota
Washington University
St Louis, Missouri
NYU Langone Medical Center
New York, New York
MD Anderson Cancer Center
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.